135 related articles for article (PubMed ID: 33752762)
21. A review of telephone consultations for head and neck cancer follow up: a patient satisfaction survey.
Stewart R; Collins L; Kerr B; Gray G; Devlin B; Black M; Ullah R
J Laryngol Otol; 2021 Sep; 135(9):815-819. PubMed ID: 34294168
[TBL] [Abstract][Full Text] [Related]
22. Prognosis: a variable parameter: dynamic prognostic modeling in head and neck squamous cell carcinoma.
van der Schroeff MP; Steyerberg EW; Wieringa MH; Langeveld TP; Molenaar J; Baatenburg de Jong RJ
Head Neck; 2012 Jan; 34(1):34-41. PubMed ID: 21322079
[TBL] [Abstract][Full Text] [Related]
23. Outpatient follow-up appointments for patients having curative treatment for cancer of the head and neck: are the current arrangements in need of change?
Kanatas A; Bala N; Lowe D; Rogers SN
Br J Oral Maxillofac Surg; 2014 Oct; 52(8):681-7. PubMed ID: 25037165
[TBL] [Abstract][Full Text] [Related]
24. The follow-up of patients with head and neck cancer: an analysis of 1,039 patients.
Kothari P; Trinidade A; Hewitt RJD; Singh A; O'Flynn P
Eur Arch Otorhinolaryngol; 2011 Aug; 268(8):1191-1200. PubMed ID: 21193920
[TBL] [Abstract][Full Text] [Related]
25. Can head and neck cancer patients be discharged after three years?
Kumar R; Putnam G; Dyson P; Robson AK
J Laryngol Otol; 2013 Oct; 127(10):991-6. PubMed ID: 24107236
[TBL] [Abstract][Full Text] [Related]
26. 'When will I see you again?' Using local recurrence data to develop a regimen for routine surveillance in post-treatment head and neck cancer patients.
Lester SE; Wight RG
Clin Otolaryngol; 2009 Dec; 34(6):546-51. PubMed ID: 20070764
[TBL] [Abstract][Full Text] [Related]
27. Thallum-201 single-proton emission CT versus CT for the detection of recurrent squamous cell carcinoma of the head and neck.
O'Tuama LA; Young Poussaint T
AJNR Am J Neuroradiol; 2001; 22(10):1983-4. PubMed ID: 11733339
[No Abstract] [Full Text] [Related]
28. Symptom-based remote assessment in post-treatment head and neck cancer surveillance: A prospective national study.
Zhang H; Hardman JC; Tikka T; Nankivell P; Mehanna H; Paleri V;
Clin Otolaryngol; 2022 Sep; 47(5):561-567. PubMed ID: 35634790
[TBL] [Abstract][Full Text] [Related]
29. A retrospective study of head and neck re-irradiation for patients with recurrent or second primary head and neck cancer: the McGill University experience.
Al-Wassia R; Vakilian S; Holly C; Sultanem K; Shenouda G
J Otolaryngol Head Neck Surg; 2015 Sep; 44(1):31. PubMed ID: 26330008
[TBL] [Abstract][Full Text] [Related]
30. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
31. The value of routine follow-up in patients treated for carcinoma of the vulva.
Oonk MH; de Hullu JA; Hollema H; Mourits MJ; Pras E; Wymenga AN; van der Zee AG
Cancer; 2003 Dec; 98(12):2624-9. PubMed ID: 14669281
[TBL] [Abstract][Full Text] [Related]
32. [Routine follow-up in patients treated of head and neck cancer].
Wierzbicka M; Waśniewska E; Jackowska J; Leszczyńska M; Szyfter W
Otolaryngol Pol; 2012; 66(2):138-47. PubMed ID: 22500505
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of current regular follow-up policy after treatment for head and neck cancer: Need for individualized and obligatory follow-up strategy.
Jung YH; Song CM; Park JH; Kim H; Cha W; Hah JH; Kwon TK; Kim KH; Sung MW
Head Neck; 2014 May; 36(5):715-21. PubMed ID: 23616261
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant stereotactic body radiotherapy±cetuximab following salvage surgery in previously irradiated head and neck cancer.
Vargo JA; Kubicek GJ; Ferris RL; Duvvuri U; Johnson JT; Ohr J; Clump DA; Burton S; Heron DE
Laryngoscope; 2014 Jul; 124(7):1579-84. PubMed ID: 24123056
[TBL] [Abstract][Full Text] [Related]
35. Follow-up after curative treatment for oral squamous cell carcinoma. A critical appraisal of the guidelines and a review of the literature.
Brands MT; Brennan PA; Verbeek ALM; Merkx MAW; Geurts SME
Eur J Surg Oncol; 2018 May; 44(5):559-565. PubMed ID: 29433990
[TBL] [Abstract][Full Text] [Related]
36. [Squamous cell carcinoma antigen. Current clinical value of a new tumor marker in head and neck cancer; preliminary results of a prospective study after 12 months].
Clasen B; Roettger D; Senekowitsch R; Menz E
Laryngol Rhinol Otol (Stuttg); 1988 Aug; 67(8):420-5. PubMed ID: 3210877
[TBL] [Abstract][Full Text] [Related]
37. Assessment and topographic characterization of locoregional recurrences in head and neck tumours.
Ferreira BC; Marques RV; Khouri L; Santos T; Sá-Couto P; do Carmo Lopes M
Radiat Oncol; 2015 Feb; 10():41. PubMed ID: 25889988
[TBL] [Abstract][Full Text] [Related]
38. High b-Value Diffusion MRI to Differentiate Recurrent Tumors from Posttreatment Changes in Head and Neck Squamous Cell Carcinoma: A Single Center Prospective Study.
Acampora A; Manzo G; Fenza G; Busto G; Serino A; Manto A
Biomed Res Int; 2016; 2016():2865169. PubMed ID: 27376081
[TBL] [Abstract][Full Text] [Related]
39. CYFRA 21-1: a suitable tumor marker in patients with head and neck cutaneous squamous cell carcinoma?
Rudhart SA; Schultz JD; Gehrt F; Pavel FL; Birk R; Hoch M; Stuck BA; Hoch S
Eur Arch Otorhinolaryngol; 2019 Dec; 276(12):3467-3475. PubMed ID: 31482332
[TBL] [Abstract][Full Text] [Related]
40. Detecting recurrent head and neck cancer using electronic nose technology: A feasibility study.
van de Goor RMGE; Hardy JCA; van Hooren MRA; Kremer B; Kross KW
Head Neck; 2019 Sep; 41(9):2983-2990. PubMed ID: 31012533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
